Comparative Pharmacology
Head-to-head clinical analysis: ELAPRASE versus MYOZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELAPRASE versus MYOZYME.
ELAPRASE vs MYOZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Idursulfase is a recombinant form of iduronate-2-sulfatase, the enzyme deficient in Hunter syndrome (MPS II). It hydrolyzes 2-sulfate groups from the terminal iduronate sulfate glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate, thereby reducing GAG accumulation in tissues.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA) that hydrolyzes glycogen to glucose in lysosomes. It replaces deficient GAA enzyme activity in patients with Pompe disease.
0.58 mg/kg IV once weekly administered over 1 hour
20 mg/kg IV every 2 weeks.
None Documented
None Documented
Terminal half-life: 6.5–8.5 hours (mean 7.5 h) in pediatric patients; supports weekly IV dosing
The terminal elimination half-life of alglucosidase alfa is approximately 2.3 hours at steady state. This short half-life necessitates weekly intravenous infusions to maintain therapeutic enzyme levels in target tissues.
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are reused or excreted
Renal elimination is the primary route of clearance for alglucosidase alfa. Following intravenous administration, the drug is cleared via catabolism into small peptides and amino acids, which are then excreted renally. Less than 5% of the administered dose is excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy